Developing Antiviral Treatments

 

Vaccines are not enough. We are blessed with three current Covid-19 vaccines, from Pfizer, Moderna and now Johnson & Johnson, with another to come from Novavax. But antiviral treatments will still be needed for those who contract the disease.

Vaccines will make the largest contributions to controlling this pandemic, but many people will still need treatment. That’s where new antiviral therapies come in. We have already heard of Gilead’s antiviral remdesivir and monoclonal antibodies developed by Regeneron Pharmaceuticals and Eli Lilly. These two treatments are making significant contributions today to treating those already infected with Covid-19.

But that is not enough. Allysia Finley, writing in The Wall Street Journal, reminds us that mutations in the virus are happening and more therapy tools are needed. These mutations, or variants, can deform the sites to which antibodies bind before they neutralize the virus. This means a constant battle to stay one step ahead of the virus.

Gilead says remdesivir appears effective against the new strains. It is the only FDA-approved antiviral for Covid-19, and the five-day infusion treatment is limited to hospital patients. Since antivirals are most effective early in an illness, developing outpatient treatments is essential to limiting the number of hospital admissions and increasing their effectiveness.

There are several different means to antiviral treatment. Remdesivir prevents the virus from duplicating its genetic code, like creating a paper jam in a copier machine. Scientists at the University of Texas last month published a study in the journal Molecular Cell in which they identified the key mechanism remdesivir uses to inhibit the virus’s replication. That could lead to the creation of more potent and perhaps ingestible drugs.

Oral medication you could take at home would be an important step forward. There is reason for some optimism this might happen. Merck is testing a oral compound, molnupiravir, that works by creating errors in the virus’ copying code. One advantage to that approach is that viruses don’t appear to develop resistance. Merck hopes to share early efficacy results from a late-stage trial by April.

The antidepressant fluvoxamine is also showing promise as an antiviral and anti-inflammatory drug. The Journal of the American Medical Association published a small randomized control trial which found that not one patient who received fluvoxamine within seven days of symptoms experienced clinical deterioration versus 8.3% of those who did in the placebo group. In another small, but non-randomized trial of infected horse racetrack workers in California found that none who took the drug got sicker, versus 12.5% who didn’t were hospitalized. These are encouraging early studies.

Another promising new drug is plitidepsin, which is derived from sea squirts and used to treat multiple myeloma in Europe and Australia. Scientists at UC-San Francisco found that it was 27.5 times as potent as remdesivir against the coronavirus in the lab. The drug is now being tested on a few dozen patients in Spain, and its manufacturer, PharmaMar, says it is seeking regulatory approval to launch larger trials.

Plitidepsin holds great promise also because it targets human proteins the virus needs to replicate, which means it could work against any new variants that might arise in the future. “If you’re targeting a human protein, it doesn’t matter how much the virus mutates,” said study co-author Nevan Krogan in an interview. “We’re hoping this gets approved quickly and it can be used in this world war fight against this virus.”

There is also work being done to develop drugs that can act as immune modulators, tamping down the overreactive immune response to the virus that often leads to major complications such as pneumonia. Merck has developed a novel immune modulator, which seems to reduce the risk of death or respiratory failure by 50% in hospitalized patients with moderate to severe illness. NIH is also testing investigational drugs provided by several pharmaceutical manufacturers that target different immune-system pathways, though the trial isn’t expected to be completed until later this year.

Operation Warp Speed instituted by the Trump administration helped advance approval of new therapies by coordinating more large randomized trials with drug makers and healthcare systems. The Biden administration needs to continue these cooperative arrangements to facilitate promising new therapies. This could hasten FDA approval of these new drugs. It is hoped that the acceleration of the usually laborious process of FDA approval will continue to make these new therapies available to the general public as soon as they show evidence of efficacy and safety.

Covid Vaccines for Children?

 

Do children need to be vaccinated for Covid-19? Currently there are no vaccines that have been approved for children under the age of 16 years. If a vaccine was approved for children under the age of 16 years, would you want your child to be vaccinated?

None of the three vaccines currently approved for use in the U.S. has been tested in children. But Moderna has begun studying its Covid-19 vaccine in children aged 6 months to 11 years in the U.S. and Canada, according to Peter Loftus, writing in The Wall Street Journal. Moderna released information recently that the first children have received doses in the study, which Moderna is conducting in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and a division of the Department of Health and Human Services (HHS).

“This pediatric study will help us assess the potential safety and immunogenicity of our Covid-19 vaccine candidate in this important younger age population,” said Moderna Chief Executive Stephane Bancel. Currently the Moderna and Johnson & Johnson vaccines are approved for use in adults age 18 years or older, while the Pfizer vaccine is approved for us in adults 16 years or older.

Covid-19 is much deadlier in the elderly population. Over 80% of deaths have occurred in individuals over 75 years old. Yet, there is a small, but important risk in children, especially those with immunocompromised health. Vaccines approved for use in children would protect them as well as further build the population-level immunity to move past pandemic restrictions.

“These kids can get coronavirus infection and the problem is they can spread this infection to other individuals,” said Tina Q. Tan, attending physician in the division of infectious diseases at Ann & Robert H. Lurie Children’s Hospital of Chicago and a professor of pediatrics at Northwestern University Feinberg School of Medicine. Dr. Tan says vaccines can be important in children because some infants and toddlers go to daycare and could transmit the virus.

This new Moderna study is a combined Phase 2 and Phase 3 trial, enrolling about 6,750 children and will be conducted in two parts. The first part will test different dose levels of the vaccine in children. Researchers will examine the safety and immune response to the various doses to determine which to carry into the second part of the study. In the second part, other study subjects will be randomized to receive two doses of either Moderna’s vaccine or a placebo, 28 days apart. Researchers will then track the safety, tolerability and effectiveness of the vaccine.

Safety is especially important in this study of children, much more than in adults, since the virus usually causes very mild or asymptomatic disease. The benefits of the vaccine are extremely high in senior adults, whose lives are definitely at risk. But these benefits are much less significant in children. Nevertheless, a safe and effective vaccine for children could be an important step in giving parents assurances that their children can return to schools without concern.

Federal health officials have suggested that if studies are positive, junior and senior-high students could get access to vaccines in the fall, followed by children of elementary-school age in early 2022.

 

Herd Immunity is Near

 

We’ve been hearing a lot about herd immunity lately, but what is it? Herd immunity occurs when enough people become immune to a disease to make its spread unlikely. As a result, the entire community is protected, even those who are not themselves immune. This is usually achieved through vaccination, but it can also occur through natural immunity.

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease (NIAID) and chief medical expert for the Biden administration, says herd immunity cannot be achieved until 70% to 85% of the population is vaccinated. Dr. Marty Makary, professor at the Johns Hopkins School of Medicine, says we’ll reach herd immunity much sooner; in fact, he says, we’re almost there already.

Writing in The Wall Street Journal, Dr. Makary says the reason we will get there much sooner is Dr. Fauci is not accounting for natural immunity. Natural immunity occurs when people become infected and get well. Their bodies develop antibodies that give them natural immunity.

The significance of this can be seen in California. Data from the California Department of Public Health released earlier this month show that while only 8.7% of the state’s population has ever tested positive for Covid-19, at least 38.5% have antibodies against Covid-19. This means many people who never got tested actually were infected and have now acquired natural immunity. These numbers were from studies between January 30 and February 20, so the actual numbers will be much higher today. Makary estimates at least half of Californians have natural immunity today.

Mayor Eric Garcetti of Los Angeles recently reported that cases in his city are down 95% and the positivity rate is only 1.7%. This vast improvement signifies the importance of natural immunity in lowering the spread of the virus. Garcetti said, “Between half and two-thirds of our population has antibodies in it now,” due to Covid exposure or vaccination.

Dr. Fauci certainly understands the importance of natural immunity. So does Dr. Rochelle Walensky, CDC Director, who has joined Fauci in playing down natural immunity. In a February 17 interview with the Journal of the American Medical Association (JAMA), she suggested that up to 20% of the population might have had Covid-19. Yet a study of antibody prevalence published soon after noted that 14% of New Yorkers had antibodies in September, even before the states’ fall and winter surges. Using the recent California data, it appears Dr. Walensky underestimated the prevalence of natural immunity by half.

Some experts claim they don’t talk about natural immunity because we shouldn’t trust it to protect us from the virus. But a recent Public Health England study found that less than 1% of 6,614 healthcare workers who had Covid-19 developed a reinfection within five months – even though many of them work directly with Covid patients.

Many experts believe that natural immunity is powerful. “Natural immunity after Covid-19 infection is likely lifelong, extrapolating from data on other coronaviruses that cause severe illness, SARS and MERS,” says Monica Gandhi, an infectious disease physician and professor at the University of California.

Why would these two scientists underestimate the significance of natural immunity?

It has become quite clear that the Biden administration wants to prolong the pandemic as long as possible, at least in the minds of Americans, for political reasons. (see CDC Credibility Gone) President Biden has already told the nation he hopes Americans will be able to have “limited gatherings” by the Fourth of July. Is this because his two most prominent medical advisors have downplayed the importance of natural immunity or because they have been told to maintain a more pessimistic outlook? What do you believe?